Reading Paige’s Playbook For Cancer Diagnostics

Paige CEO Andy Moye talked to Medtech Insight about the company’s current offerings in the prostate and breast cancer markets, as well as its future ambitions and general strategy.

Paige has been developing algorithms that can detect indiscernible-to-the-eye differences in hematoxylin and eosin-stained (H&E) biopsy slides, aiding doctors in the diagnosis of cancer.

The company has had a frantic past four years. Launches and approvals both in the US and European markets – where it has obtained eight CE marks – have helped...

More from AI

More from Digital Technologies